A Case For The Use Of Psilocybin In Palliative Care
The drug that reconciles death as part of the cycle of life
Psilocybin and psilocin are the main psychoactive components of magic mushrooms.
Psilocybin has no known long-term side effects. It is not addictive, and it produces long-lasting antidepressive effects. In palliative care, 87% of volunteers have reported an increase in life satisfaction.
And though the data is consistent with its benefits, psilocybin is still registered as a schedule I drug in the US. Yet, with cannabis legalization, people are realizing its potential in healthcare. Besides, the legalization has opened the doors for psychedelic research.
Below, I arranged a list of why and how psilocybin can be used in palliative care.
The Overprescription Of Antidepressants And Their Impact On Human Health
Many anti-anxiety medications (AAM) and antidepressants (AD) increase the chances of physical dependency. What makes it more alarming is that AD users include 24% of women aged 60+ in the US and 13% of the US general population. In fact, AD prescription has more than doubled in the last 10 years. A prescription rate comparable to the opioid crisis.
A study by The Journal of Addictive Behaviors showed that up to 55% of AD users experience some difficulty in quitting them. And ironically, a common symptom of AD and AAM withdrawal is depression and anxiety.
Psilocybin has shown no signs of physiological dependency in its users. A pilot study showed recovery from nicotine addiction. Yet, we know psilocybin has to be investigated on its potential use as an anti-anxiety treatment, but literature points towards its benefits.